Sinovac Biotech sought to expand the use of its COVID-19 vaccine on children ages 3 to 17, according to FDA.
The Food and Drug Administration (FDA) said that Sinovac Biotech sought to expand the use of its COVID-19 vaccine on children ages 3 to 17.
During the Cabinet briefing aired early Wednesday, FDA Director-General Eric Domingo said that Sinovac Biotech had applied for an amendment to the emergency use authorization (EUA) of its COVID-19 vaccine in order for it to be used on children aged 3 to 17.
“The Sinovac, just this afternoon (July 6), they already applied for an amendment of their EUA to include children. In this case, children from three to 17 years old. This is another potential vaccine that can be used for the pediatric age group,” Domingo said.
Under its current emergency use authorization in the Philippines, Sinovac Biotech’s CoronaVac COVID-19 vaccine can only be used for individuals aged 18 and above.
So far, the COVID-19 vaccine jointly developed by Pfizer and BioNTech had been allowed by the Philippine Food and Drug Administration to be used for 12 years old and older.
Domingo also said that the country’s Vaccine Experts Panel under the Department of Science and Technology (DOST) was currently studying the amendment application of Sinovac Biotech.
“Our vaccine experts are now taking a look at the data and of course asking questions to the proponents and getting more information. So ito ay inaaral natin within the month to see if we will be able to allow the use of Sinovac in children,” Domingo said.
What can you say about this? Let us know in the comments below.